Teriflunomide Attenuates Immunopathological Changes in the Dark Agouti Rat Model of Experimental Autoimmune Encephalomyelitis
Authors:
- Garth E. RingheimGRGarth E. Ringheim
- Lan LeeLLLan Lee
- Lynn Laws-RickerLLLynn Laws-Ricker
- Tomas DeloheryTDTomas Delohery
- Li LiuLLLi Liu
- Donghui ZhangDZDonghui Zhang
- Nicholas CollettiNCNicholas Colletti
- Timothy J. SoosTSTimothy J. Soos
- Barbara FanelliBFBarbara Fanelli
- Nian TianNTNian Tian
- Christopher W. ArendtCAChristopher W. Arendt
Open Access
- 1 January 2013
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 4, 169
Abstract
Teriflunomide is an oral disease-modifying therapy recently approved in several locations for relapsing forms of multiple sclerosis. To gain insight into the effects of teriflunomide, immunocyte population changes were measured during progression of experimental autoimmune encephalomyelitis in Dark Agouti rats. Treatment with teriflunomide attenuated levels of spinal cord-infiltrating T cells, natural killer cells, macrophages, and neutrophils. Teriflunomide also mitigated the disease-induced changes in immune cell populations in the blood and spleen suggesting an inhibitory effect on pathogenic immune responses.Keywords
This publication has 52 references indexed in Scilit:
- Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosisNeurology, 2013
- Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosisMultiple Sclerosis Journal, 2012
- An aggregation sensing reporter identifies leflunomide and teriflunomide as polyglutamine aggregate inhibitorsHuman Molecular Genetics, 2011
- Polyclonal Treg cells modulate T effector cell traffickingEuropean Journal of Immunology, 2011
- Multiple sclerosis as a neurodegenerative disease: pathology, mechanisms and therapeutic implicationsCurrent Opinion in Neurology, 2011
- T cells in multiple sclerosis and experimental autoimmune encephalomyelitisClinical and Experimental Immunology, 2010
- Methylprednisolone inhibits IFN-γ and IL-17 expression and production by cells infiltrating central nervous system in experimental autoimmune encephalomyelitisJournal of Neuroinflammation, 2009
- Neutrophil secretion products pave the way for inflammatory monocytesBlood, 2008
- The Th17–ELR+ CXC chemokine pathway is essential for the development of central nervous system autoimmune diseaseJournal of Experimental Medicine, 2008
- Multiple sclerosis: a complicated picture of autoimmunityNature Immunology, 2007